

ASSESSING FINANCIAL DIFFICULTY IN PATIENTS WITH BLOOD CANCERS

Patient Eligibility

Patients must have current diagnosis of chronic lymphocytic leukemia (CLL) and/or multiple myeloma (MM)

Patients' medical records must be available to the registering institution.

Eligible patients must have been prescribed drug-based anticancer therapy, whether administered orally or by infusion, within the prior 12 months. Specifically, eligible patients are those who:

- Are presently being treated with infused or orally-administered anticancer therapy, OR
- Completed infused or orally-administered anti-cancer therapy in the past 12 months, OR
- Were prescribed infused or orally-administered anticancer therapy within the prior 12 months yet chose to forego treatment

Not currently enrolled in a clinical trial in which drug is supplied by the study.

Patients with psychiatric illness or other mental impairment that would preclude their ability to give informed consent or to respond to the telephone survey are not eligible.


Patients must be able to read and comprehend English or Spanish.

Age \geq 18 years

**Required Initial
Laboratory Values**

None

Patient level Schema




Please refer to the full protocol text for a complete description of the eligibility criteria and intervention plan.

Site Eligibility

- Intent to complete the A231602CD Practice Survey ([Appendix I](#))
- Access to patient medical records: Registering institution must have access to patient medical records if recruiting patients at any other clinic (as medical abstraction is required for collecting study data).
- Sites must be able to conduct informed consent discussion in Spanish, if necessary.

Site level Schema



Please refer to the full protocol text for a complete description of the site eligibility criteria and study implementation

3.0 PATIENT SELECTION

For questions regarding eligibility criteria, see the Study Resources page. Please note that the Study Chair cannot grant waivers to eligibility requirements.

3.1 On-Study Guidelines

This clinical trial can fulfill its objectives only if patients appropriate for this trial are enrolled. All relevant medical and other considerations should be taken into account when deciding whether this protocol is appropriate for a particular patient.

3.2 Patient Eligibility Criteria

- ___ **3.2.1 Documentation of disease:** Patients must have current diagnosis of chronic lymphocytic leukemia (CLL) and/or multiple myeloma (MM).
- ___ **3.2.2 Patients' medical records must be available to the registering institution.**
- ___ **3.2.3 Eligible patients must have been prescribed drug-based anticancer therapy, whether administered orally or by infusion, within the prior 12 months.** Specifically, eligible patients are those who:
 - Are presently being treated with infused or orally-administered anticancer therapy, OR
 - Completed infused or orally-administered anti-cancer therapy in the past 12 months, OR
 - Were prescribed infused or orally-administered anticancer therapy within the prior 12 months yet chose to forego treatment.
- ___ **3.2.4 Not currently enrolled in a clinical trial in which drug is supplied by the study.**
- ___ **3.2.5 Patients with psychiatric illness or other mental impairment that would preclude their ability to give informed consent or to respond to the telephone survey are not eligible.**
- ___ **3.2.6 Patients must be able to read and comprehend English or Spanish.**
- ___ **3.2.7 Age \geq 18 years**

3.3 Site Eligibility Criteria

- ___ **3.3.1 Intent to complete the A231602CD Practice Survey ([Appendix I](#)).**
- ___ **3.3.2 Access to patient medical records:** Registering institution must have access to patient medical records, either on site or via request from other institutions, if recruiting patients at a site (as medical abstraction is required for collecting study data).
- ___ **3.3.3 Sites seeking to enroll Spanish- speaking patients must have Spanish speaking staff on site or through the use of a translation service to be able to conduct the informed consent discussion in Spanish.**